Progyny, Inc. (NASDAQ:PGNY – Get Rating) Director Norman Payson sold 6,618 shares of the firm's stock in a transaction on Wednesday, August 3rd. The shares were sold at an average price of $32.27, for a total value of $213,562.86. Following the transaction, the director now directly owns 411,412 shares of the company's stock, valued at approximately $13,276,265.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Norman Payson also recently made the following trade(s):
Get Progyny alerts:- On Wednesday, July 20th, Norman Payson sold 6,618 shares of Progyny stock. The shares were sold at an average price of $33.40, for a total value of $221,041.20.
- On Wednesday, July 6th, Norman Payson sold 6,618 shares of Progyny stock. The shares were sold at an average price of $29.38, for a total value of $194,436.84.
- On Wednesday, June 22nd, Norman Payson sold 6,618 shares of Progyny stock. The shares were sold at an average price of $27.35, for a total value of $181,002.30.
- On Wednesday, May 25th, Norman Payson sold 6,618 shares of Progyny stock. The shares were sold at an average price of $32.09, for a total value of $212,371.62.
- On Wednesday, May 11th, Norman Payson sold 6,618 shares of Progyny stock. The stock was sold at an average price of $33.45, for a total value of $221,372.10.
Progyny Price Performance
PGNY opened at $41.15 on Friday. The stock has a 50-day moving average price of $30.23 and a 200-day moving average price of $37.32. The firm has a market cap of $3.78 billion, a PE ratio of 89.46, a P/E/G ratio of 15.71 and a beta of 1.85. Progyny, Inc. has a 1 year low of $25.67 and a 1 year high of $68.32.
Progyny (NASDAQ:PGNY – Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.04. The firm had revenue of $195.00 million during the quarter, compared to analyst estimates of $190.51 million. Progyny had a return on equity of 18.11% and a net margin of 7.39%. Progyny's quarterly revenue was up 51.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.19 EPS. As a group, sell-side analysts anticipate that Progyny, Inc. will post 0.09 EPS for the current year.Hedge Funds Weigh In On Progyny
Several large investors have recently modified their holdings of PGNY. National Bank of Canada FI purchased a new position in shares of Progyny in the 2nd quarter worth about $29,000. First Horizon Advisors Inc. raised its position in Progyny by 1,469.4% in the 4th quarter. First Horizon Advisors Inc. now owns 769 shares of the company's stock worth $38,000 after buying an additional 720 shares during the last quarter. Fifth Third Bancorp raised its position in Progyny by 1,532.4% in the 4th quarter. Fifth Third Bancorp now owns 1,208 shares of the company's stock worth $61,000 after buying an additional 1,134 shares during the last quarter. Steward Partners Investment Advisory LLC raised its position in Progyny by 44.8% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,209 shares of the company's stock worth $61,000 after buying an additional 374 shares during the last quarter. Finally, Lazard Asset Management LLC purchased a new position in Progyny in the 1st quarter worth about $62,000. Hedge funds and other institutional investors own 82.51% of the company's stock.
About Progyny
(Get Rating)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Further Reading
- Get a free copy of the StockNews.com research report on Progyny (PGNY)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.